Nu Planet Pharmaceutical Radioisotopes
Nu Planet innovates in nuclear physics, producing cost-effective, scalable rare isotopes for pharma, energy, space & defense sectors.
Founded
2021Nu Planet innovates in nuclear physics, producing cost-effective, scalable rare isotopes for pharma, energy, space & defense sectors.
Nu Planet Pharmaceutical Radioisotopes, founded by Dr. Steve Howe, focuses on innovating within the nuclear physics sector to produce cost-effective and scalable rare isotopes. Their core mission is to revolutionize the supply chain for isotopes used in pharmaceuticals, energy, space, and defense industries. By leveraging a multi-isotope production platform, Nu Planet aims to significantly reduce costs and create a sustainable economic advantage in a multi-billion-dollar market.
Dr. Steve Howe, with affiliations to Los Alamos and Idaho Labs, leads the company. Nu Planet has attracted notable investors due to its groundbreaking approach and potential market impact. Key achievements include the development of a scalable production process that outperforms current cost benchmarks. The company's innovations promise to enhance the availability and affordability of critical isotopes, thereby driving advancements across multiple high-tech industries.
Companies similar to Nu Planet Pharmaceutical Radioisotopes include Alpha Source, NorthStar Medical Radioisotopes, Arizona Isotope Science Research and Niowave.
Nu Planet Pharmaceutical Radioisotopes was founded in 2021.
Nu Planet Pharmaceutical Radioisotopes' headquarters is located in Scottsdale, AZ, US.
Nu Planet Pharmaceutical Radioisotopes' most recent funding round was for $1.2M (USD) in January 2022.
As of Jan 1, 2022, Nu Planet Pharmaceutical Radioisotopes has disclosed funding of $1.2M (USD). Undisclosed round amounts are excluded.
Nu Planet Pharmaceutical Radioisotopes has 5 employees as of Feb 4, 2024.
Niowave
niowaveinc.com
